Clinical Trial Update: MK-3475/BCG in High Risk Superficial Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pembrolizumab with Bacillus Calmette-Guérin in high-risk non-muscle invasive bladder cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Southern Illinois University | Conditions: Bladder Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-09-03